Advice
Development of this evidence summary
The evidence summary: process guide (2017) sets out the process NICE uses to select topics for evidence summaries and details how the summaries are developed, quality assured and approved for publication.
Expert advisers
Christopher Denton, Consultant Rheumatologist, University College London Division of Medicine and Royal Free London NHS Foundation Trust.
Ariane Herrick, Professor of Rheumatology, University of Manchester and Honorary Consultant Rheumatologist, Salford Royal NHS Foundation Trust.
Neil McHugh, Consultant Rheumatologist, Royal National Hospital for Rheumatic Diseases.
Declarations of interest
Christopher Denton undertakes ad hoc personal consultancy in the area of clinical trial design and new potential scleroderma therapy including the following commercial organisations: Actelion, Pfizer, GlaxoSmithKline, Bayer, Sanofi-Aventis, Genentech-Roche, Merck-Serono, CSL Behring and Inventiva.
His department has received research grant funding for work in the area of scleroderma from the following commercial organisations: Actelion, CSL Behring, Inventiva and GlaxoSmithKline.
Ariane Herrick has received research funding from Actelion and has spoken at meetings sponsored by Actelion. Payments were to the University of Manchester, her employer.
Neil McHugh has acted on an advisory board for an educational programme delivered by AbbVie. He has also received grant funding on behalf of his NHS organisation for investigator initiated projects sponsored by Celgene.
|
About this evidence summary Evidence summaries provide a summary of the best available published evidence for selected new medicines, unlicensed medicines or off-label use of licensed medicines. The summaries assess the strengths and weaknesses of the best available evidence to inform health professionals and commissioners' decision-making. This summary is not NICE guidance. |
ISBN: 978-1-4731-2376-2